Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
نویسندگان
چکیده
منابع مشابه
Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
The expansion of our understanding of tumor immunity and the recent success of new cancer immunotherapy has reignited the hope that we can treat cancer effectively with immunotherapeutic approaches. Immune checkpoint inhibitors have shown significant efficacy in the treatment of some solid and hematologic malignancies. Encouraged by recent success in some other types of malignancies, many clini...
متن کاملImmune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status
Introduction Large cell neuroendocrine carcinomas (LCNEC) are a group of rare high grade neuroendocrine tumors that often behave clinically like small cell carcinoma (SCLC) and are treated as such. No major advancement in the management of these tumors has occurred in the last 30 years. Methods We present a case series of three cases from Markey Cancer center along with a review of 13 publish...
متن کاملCheckpoint inhibitors in gastrointestinal cancers: Expectations and reality
Immune checkpoint inhibitors represent revolutionary anti-cancer agents, being rapidly approved in different malignancies and settings. Gastrointestinal (GI) cancers represent a wide variety of tumors with specific characteristics and different responses to various therapeutic alternatives; while some are chemo-sensitive others are chemo-resistant and only respond to more aggressive cytotoxic r...
متن کاملUpdate on immune checkpoint inhibitors in gynecological cancers
In recent years, progress in our understanding of immune-modulatory signaling pathways in immune cells and the tumor microenvironment (TME) has led to rejuvenated interest in cancer immunotherapy. In particular, immunotherapy targeting the immune checkpoint receptors such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell-death 1 (PD-1), and programmed cell-death ligand 1 ...
متن کاملMechanisms of immune evasion and current status of checkpoint inhibitors in non‐small cell lung cancer
In the past several years, immunotherapy has emerged as a viable treatment option for patients with advanced non-small cell lung cancer (NSCLC) without actionable driver mutations that have progressed on standard chemotherapy. We are also beginning to understand the methods of immune evasion employed by NSCLC which likely contribute to the 20% response rate to immunotherapy. It is also yet uncl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Cancer
سال: 2017
ISSN: 1837-9664
DOI: 10.7150/jca.18470